Objetivo Prostate cancer is now the leading cause of cancer related deaths in most European countries. However, knowledge of the underlying mechanisms is still scarce. The overall aim of this project is to identify new oncogenes involved in prostate cancer and assess their potential as clinical markers. The focus will be the E2F3 transcription factor that has an established role in cell cycle progression and has recently been proposed as a candidate oncogene for bladder cancer. Initial studies indicate that 70% of prostate cancers over-express E2F3.We will combine tissue microarray (TMA) staining data from 1200 prostate cancer patients with clinical data, and statistically analyse the correlation. We will also test the hypothesis that down regulation of pBR is needed for upregulation of E2F3 to have an impact, by studies of the pBR levels in parallel with the E2F3 analysis on the TMAs. We will determine whether the upregulation is associated with increased copy number of the gene by flourescence in situ hybridisation ( FISH) onto TMAs and, finally, the biological role of E2F3 in the development of prostate cancer will be investigated by siRNA technology in prostate cancer cell lines that over-express E2F3. Ámbito científico medical and health sciencesclinical medicineoncologyprostate cancer Programa(s) FP6-MOBILITY - Human resources and Mobility in the specific programme for research, technological development and demonstration "Structuring the European Research Area" under the Sixth Framework Programme 2002-2006 Tema(s) MOBILITY-2.1 - Marie Curie Intra-European Fellowships (EIF) Convocatoria de propuestas FP6-2002-MOBILITY-5 Consulte otros proyectos de esta convocatoria Régimen de financiación EIF - Marie Curie actions-Intra-European Fellowships Coordinador INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL Aportación de la UE Sin datos Dirección 123 OLD BROMPTON ROAD LONDON Reino Unido Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos
